Clinical trials: Cognitive Function, Preclinical
Preclinical Alzheimer's Disease, Alzheimer Disease
Alzheimer's Tau Platform: Master Protocol
The goal of the Alzheimer's Tau Platform (ATP) is to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with the anti-amyloid monoclonal antibody, donanemab, in adults aged 50-80 with late…
- Conditions
- Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
- Trial name
- ATP (NCT06957418)
- Testing
- AADvac1, Tau2
- Where
- 7 sites in United States
- Volunteers
- 900 people
- Sponsor
- Paul S. Aisen
Preclinical Alzheimer's Disease
Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease
The purpose of this study is to assess the safety and efficacy of gemfibrozil in modulating microRNA-107 levels for the prevention of Alzheimer's disease in subjects with intact cognition and mild cognitive impairment
- Trial name
- NCT02045056
- Testing
- Gemfibrozil
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Gregory Jicha, 323-5550
Alzheimer Disease, Cognitive Decline Due to Alzheimer Disease
Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia
Two-year double-masked trial of over-the-counter dosage of naproxen sodium vs placebo in 200 cognitively normal participants with a parental or multiplex first-degree family history Alzheimer's disease (AD) dementia.
- Conditions
- Alzheimer Disease, Cognitive Decline Due to Alzheimer Disease, Mild Cognitive Impairment Due to Alzheimer Disease
- Trial name
- NCT02702817
- Testing
- Naproxen
- Where
- Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Alzheimer Disease, Mild Cognitive Impairment (MCI)
Communication Regarding Preclinical Dementia Diagnostic and Diagnostic Disclosure Among Patients with MCI and SCD
The study investigate what information individuals with SCD or MCI and their co-participant would like to receive during pre-diagnostic counseling and diagnostic disclosure, and how this information should be conveyed.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
- Trial name
- NCT06621758
- Testing
- questionnaire
- Volunteers
- 120 people
- Sponsor
- Danish Dementia Research Centre
Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD)
Predicting Pre-dementia
The goal of this observational study is to learn how well a multimodal "Progression and Risk" (PR) model can predict and stage early mild cognitive impairment (MCI) due to Alzheimer's disease in cognitively normal or very mildly…
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD), Alzheimer Disease (AD), APOE-4 Positive
- Trial name
- NCT07516119
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Prevention Research Consortium Corp.
Subjective Cognitive Impairment, Mild Cognitive Impairment
Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative Disease
The purpose of this study is to investigate the beneficial effects of regular exercise and the impact of food supplement carnosine on cognitive, motoric and metabolic functions as well as on specific biologically active…
- Conditions
- Subjective Cognitive Impairment, Mild Cognitive Impairment, Parkinson Disease, Healthy Volunteers
- Trial name
- NCT03330470
- Testing
- exercise, carnosine supplementation, stretching
- Where
- 3 sites in Slovakia, Taiwan
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Slovak Academy of Sciences
Huntington Disease
Clinical Study to Monitor Plasma Levels of 24OHC in Subject with HD
A 2-year clinical longitudinal study to measure plasma concentrations of 24S-hydroxycholesterol, a brain-derived cholesterol catabolite, in subjects with Huntington disease, from the presymptomatic to the symptomatic stages.
- Trial name
- Chol-HD (NCT04257513)
- Testing
- Brain MRI
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Alzheimers Disease
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in…
- Trial name
- GS1 (NCT02565511)
- Testing
- CAD106 Immunotherapy, CNP520, Alum
- Where
- 129 sites in United States, Australia and 8 more
- Volunteers
- 480 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease, Functional Food
Non-pharmacological Intervention for Preclinical Alzheimer's Disease
Alzheimer's disease (AD) is the most common form of neurodegenerative disorders leading to dementia. Currently, there has been no effective drugs targeting this disease.
- Conditions
- Alzheimer Disease, Functional Food, Subjective Cognitive Decline, Intervention
- Trial name
- NCT04279418
- Testing
- Mixed functional foods supplementation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- XuanwuH 2